[1] Vanlemmens C,Dimartino V,Milan C,et al. Immediate listing for liver transplantation versus standaard care for Child-Pugh stage B alcoholic cirrhosis：a randomized trial. Ann Intern Med,2009,150（3）:153-161.
[2] Pugh RN,Murraylyon IM,Dawson JL,et al. Transection of the oesophagus for bleeding esophageal varices. Br J Surg,1973,60（8）：646-649.
[3] 邱德凯.不断改进肝脏储备功能检测的研究.中华消化杂志,2007,27（6）：361-362.
[4] Strahl S,Maier KP. Risk-classification in liver cirrhosis. Praxis （Bern 1994）,2006,95（34）：1275-1281.
[5] Kamath PS,Wiesner RH,Malinchoc M,et al. A model to predict survival in patients with end-stage liver disease.Hepatology,2001,33（2）：464-470.
[6] Srikureja W,Kyulo NL,Runyon BA,et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol,2005,42（5）：700-706.
[7] Huo TI,Lee SD,Lin HC. Selecting an optimal prognostic system for liver cirrhosis：the model for end-stage liver disease and beyond. Liver Int,2008,28（5）：606-613.
[8] Tsai MH,Peng YS,Chen YC,et al. Low serum concentration of apolipoprotein A-1 is an indicator for poor prognosis in cirrhotic patients with severe sepsis. J Hepatol,2009,50（5）,906-915.
[9] Biggins SW,Rodriguex HJ,Bacchetti P,et al. Serum sodium predicts mortality in patients listed for liver transplantation.Hepatology,2005,41（1）：32-39.
[10] Luca A,Angermayr B,Bertolini G,et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl,2007,13（8）：1174-1180.
[11] Huo TI,Wang YW,Yang YY,et al. Model for end stage liver disease score to serum sodium ratio as a prognostic predictor and its correlation with portal pressure in patients with liver cirrrhosis. Liver Int,2007,27（4）：498-506.
[12] Huo TI,Lin HC,Huo SC,et al. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl,2008,14（6）：837-844.
[13] Vaa BE,Asrani SK,Dunn W,et al. Influence of serum sodium on MELD based survival prediction in alcoholic hepatitis. Mayo Clin Pro,2011,85（1）：37-42.
[14] Gex L,Bernard C,Spahr L. Child-Pugh,MELD and Maddrey scores. Rev Med Suisse,2010,6（264）：1803-1804.
[15] Akriviadis E,Botla R,Briggs W,et al. Pentoxifylline improves short-term survival in severe acute hepatitis：a double-blind, placebo-controlled trial. Gastroenterology,2000,119（6）：1637-1648.
[16] Rambaldi A,Saconsto HH,Christensen E,et al. Systematic review：glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther,2008,27（12）：1167-1178.
[17] Forrest EH,Evans CD,Stewart S,et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut,2005,54（8）：1174-1179.
[18] Altamirano GJ,Zapata IL,Augustin RS,et al. Three prognostic scales;clinical utility and prediction of intrahospital survival in alcoholic hepatitis. Rev Gastroenterol Mex,2009,74（1）：18-25.
[19] Forrest EH,Morris AJ,Stewart S,et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut,2007,56（12）：1743-1746.
[20] Louvet A,Naveau S,Abdelnour M,et al. The Lille model： a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology,2007,45（6）：1348-1354.
[21] Huo TI,Wu JC,Lin HC,et al. Evaluation of the increase in model for end-stage liver disease（△MELD） score over time as a prognostic predictor in patients with advanced cirrhosis： risk factor analysis and comparison with initial MELD and Child Turcotte Pugh score. J Hepatol,2005,42（6）：826-832.
[22] Sharma P,Kumar A,Sharma BC,et al. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival：an open label trial. J Hepatol,2009,50（3）：584-591.
（校对：陈从新） |
